Literature DB >> 22749677

A brief history of anti-VEGF for the treatment of ocular angiogenesis.

Leo A Kim1, Patricia A D'Amore.   

Abstract

In 1994, The American Journal of Pathology published a key article reporting that hypoxic retina produces vascular endothelial growth factor (VEGF), suggesting a role for VEGF in ocular neovascularization. Subsequent developments in anti-VEGF treatment for neovascular eye disease have improved visual outcomes and changed the standard of care in retinal medicine and ophthalmology.
Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22749677      PMCID： PMC5691342          DOI： 10.1016/j.ajpath.2012.06.006

Source DB:  PubMed          Journal:  Am J Pathol        ISSN： 0002-9440            Impact factor:   4.307


  40 in total

1.  Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema.

Authors:  Masoud Soheilian; Kiumars Heidari Garfami; Alireza Ramezani; Mehdi Yaseri; Gholam A Peyman
Journal:  Retina       Date:  2012-02       Impact factor: 4.256

2.  Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy.

Authors:  Mohamed Al-Shabrawey; Manuela Bartoli; Azza B El-Remessy; Daniel H Platt; Sue Matragoon; M Ali Behzadian; Robert W Caldwell; Ruth B Caldwell
Journal:  Am J Pathol       Date:  2005-08       Impact factor: 4.307

3.  Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function.

Authors:  Alexander G Marneros; Jie Fan; Yoshihito Yokoyama; Hans Peter Gerber; Napoleone Ferrara; Rosalie K Crouch; Bjorn R Olsen
Journal:  Am J Pathol       Date:  2005-11       Impact factor: 4.307

4.  Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization.

Authors:  K Spilsbury; K L Garrett; W Y Shen; I J Constable; P E Rakoczy
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

5.  VEGF-Trap: a VEGF blocker with potent antitumor effects.

Authors:  Jocelyn Holash; Sam Davis; Nick Papadopoulos; Susan D Croll; Lillian Ho; Michelle Russell; Patricia Boland; Ray Leidich; Donna Hylton; Elena Burova; Ella Ioffe; Tammy Huang; Czeslaw Radziejewski; Kevin Bailey; James P Fandl; Tom Daly; Stanley J Wiegand; George D Yancopoulos; John S Rudge
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

6.  Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.

Authors:  Kazuaki Nishijima; Yin-Shan Ng; Lichun Zhong; John Bradley; William Schubert; Nobuo Jo; Jo Akita; Steven J Samuelsson; Gregory S Robinson; Anthony P Adamis; David T Shima
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

7.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

8.  Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate.

Authors:  A P Adamis; D T Shima; M J Tolentino; E S Gragoudas; N Ferrara; J Folkman; P A D'Amore; J W Miller
Journal:  Arch Ophthalmol       Date:  1996-01

9.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Authors:  L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park
Journal:  N Engl J Med       Date:  1994-12-01       Impact factor: 91.245

10.  Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors.

Authors:  Magali Saint-Geniez; Arindel S R Maharaj; Tony E Walshe; Budd A Tucker; Eiichi Sekiyama; Tomoki Kurihara; Diane C Darland; Michael J Young; Patricia A D'Amore
Journal:  PLoS One       Date:  2008-11-03       Impact factor: 3.240
View more
  51 in total

1.  Identification of RUNX1 as a Mediator of Aberrant Retinal Angiogenesis.

Authors:  Jonathan D Lam; Daniel J Oh; Lindsay L Wong; Dhanesh Amarnani; Cindy Park-Windhol; Angie V Sanchez; Jonathan Cardona-Velez; Declan McGuone; Anat O Stemmer-Rachamimov; Dean Eliott; Diane R Bielenberg; Tave van Zyl; Lishuang Shen; Xiaowu Gai; Patricia A D'Amore; Leo A Kim; Joseph F Arboleda-Velasquez
Journal:  Diabetes       Date:  2017-04-11       Impact factor: 9.461

2.  Pathogenic role and therapeutic potential of pleiotrophin in mouse models of ocular vascular disease.

Authors:  Weiwen Wang; Michelle E LeBlanc; Xiuping Chen; Ping Chen; Yanli Ji; Megan Brewer; Hong Tian; Samantha R Spring; Keith A Webster; Wei Li
Journal:  Angiogenesis       Date:  2017-04-26       Impact factor: 9.596

3.  Intravitreal vascular endothelial growth factor.

Authors:  Thomas Bertelmann; Stephan Schulze; Reka Bölöni; Walter Sekundo; Sebastian Irle; Thomas Stief; Stefan Mennel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-02-04       Impact factor: 3.117

4.  Age-related macular degeneration and mortality: the Melbourne Collaborative Cohort Study.

Authors:  M B McGuinness; R P Finger; A Karahalios; R H Guymer; D R English; E W Chong; A M Hodge; L D Robman; G G Giles; J A Simpson
Journal:  Eye (Lond)       Date:  2017-08-18       Impact factor: 3.775

5.  Identification of a stable molecular signature in mammary tumor endothelial cells that persists in vitro.

Authors:  Lin Xiao; J Chuck Harrell; Charles M Perou; Andrew C Dudley
Journal:  Angiogenesis       Date:  2013-11-21       Impact factor: 9.596

Review 6.  Nanoengineering of therapeutics for retinal vascular disease.

Authors:  Nivriti Gahlaut; Sandra Suarez; Md Imam Uddin; Andrew Y Gordon; Stephanie M Evans; Ashwath Jayagopal
Journal:  Eur J Pharm Biopharm       Date:  2015-05-28       Impact factor: 5.571

7.  Endothelium-derived semaphorin 3G attenuates ischemic retinopathy by coordinating β-catenin-dependent vascular remodeling.

Authors:  Dan-Yang Chen; Ning-He Sun; Xiang Chen; Jun-Jie Gong; Song-Tao Yuan; Zi-Zhong Hu; Nan-Nan Lu; Jakob Körbelin; Kohji Fukunaga; Qing-Huai Liu; Ying-Mei Lu; Feng Han
Journal:  J Clin Invest       Date:  2021-02-15       Impact factor: 14.808

8.  Loss of caveolin-1 causes blood-retinal barrier breakdown, venous enlargement, and mural cell alteration.

Authors:  Xiaowu Gu; Steven J Fliesler; You-Yang Zhao; William B Stallcup; Alex W Cohen; Michael H Elliott
Journal:  Am J Pathol       Date:  2013-12-08       Impact factor: 4.307

Review 9.  Rethinking Nuclear Receptors as Potential Therapeutic Targets for Retinal Diseases.

Authors:  Mayur Choudhary; Goldis Malek
Journal:  J Biomol Screen       Date:  2016-07-28

10.  Phosphatidylserine (PS) Is Exposed in Choroidal Neovascular Endothelium: PS-Targeting Antibodies Inhibit Choroidal Angiogenesis In Vivo and Ex Vivo.

Authors:  Tao Li; Bogale Aredo; Kaiyan Zhang; Xin Zhong; Jose S Pulido; Shusheng Wang; Yu-Guang He; Xianming Huang; Rolf A Brekken; Rafael L Ufret-Vincenty
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-11       Impact factor: 4.799
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.